To explore the molecular pathways that are differently expressed in ovarian cancer cells resistant to PARPi first, we analyzed the RNAseq results from the dataset GSE235980 that used UWB1.289 (BRCA1-deficient) and UWB1.289 + BRCA1 (BRCA1-complemented) cells treated with Olaparib for 11 months to select PARPi-resistant cells. This evidence concerns the gene BRCA1 and ovarian carcinoma.